MFA Launches MulteFire 1.0 Certification Program to Support Interoperable Device Ecosystem for Private Wireless Networks
19.11.2020 17:00:00 EET | Business Wire | Press release
The MulteFire Alliance (MFA) today announced the launch of its MulteFire 1.0 Certification Program. In addition, the first customer premise equipment (CPE) device has been certified compliant.
With MulteFire technology, organizations can now cost-effectively deploy their own private LTE network and realize the benefits of better capacity, coverage, mobility and built-in security needed for industry 4.0 use cases.
The MulteFire 1.0 specification defines LTE operation in unlicensed and shared spectrum bands, including the global 5 GHz band. The certification program tests eNodeBs together with UEs for conformance with the MulteFire 1.0 specification to ensure an interoperable, global device ecosystem for use in unlicensed or shared radio spectrum. By removing the need for licensed spectrum, MulteFire will help to lower entry cost and accelerate high-speed, secure private wireless networking deployment.
MulteFire technology opens up an entirely new range of private wireless use cases that add to existing deployment scenarios in asset-intensive industries. New opportunities include rapid deployment situations such as field hospitals and emergency response, as well as temporary systems for pop-up events, touring, cultural and sports programs. In addition, MulteFire can also be used to complement existing private wireless deployment in licensed spectrum, for example to add capacity by tapping into the large bandwidth available in the unlicensed 5 GHz spectrum band.
“The MulteFire 1.0 Certification Program is a significant milestone for the Alliance and represents the diligent efforts of our Certification Working Group to bring this program to the industry,” said Mazen Chmaytelli, president, MFA. “We are also excited to share that we have already certified the first MulteFire radio and device solutions from Nokia as compliant.”
“By enabling private wireless connectivity in unlicensed and shared spectrum, we enable even more enterprises to deploy their own private LTE and 5G networks,” said Stephan Litjens, General Manager, Nokia Digital Automation Cloud and MFA board chair. “As a founding member of MFA, we’re firmly at the forefront of this initiative – firstly with certification of our own MulteFire CPE offering – and also to accelerate a device ecosystem for the benefit of enterprise digital transformation.”
Through overlapping membership with 3GPP, the MFA is also supporting efforts for 5G NR standalone operation in unlicensed spectrum. A recent ABI Research white paper quantifies the total addressable market size for private network equipment (for industrial manufacturing, ports, logistics, mining, and energy) in LTE and 5G at $32.37B by 2030. ABI also states that by 2030 more than half of industry verticals’ private networks using LTE or 5G will be deployed in unlicensed, shared or dedicated licensed spectrum.
DEKRA Named Authorized Test Lab for MulteFire 1.0
DEKRA, an MFA member and leader in product certification, conducted the certification testing for MulteFire 1.0 and DEKRA Malaga has been named an Authorized Test Lab for the MulteFire 1.0 Certification Program. DEKRA was already named the first Authorized Test Lab for the MulteFire 1.9 GHz sXGP Certification Program launched in Japan at the end of 2019.
“DEKRA is very pleased to continue its partnership with the MFA with the addition of MulteFire 1.0 testing to our services offering, and we are happy to contribute to the success of the MulteFire ecosystem,” said Andrés Moreno, Managing Director, DEKRA Testing and Certification Spain.
The MFA Certification Program is available to all MFA members. Upon device certification, companies will receive the ‘MulteFire Certified’ logo and certification mark for product promotion and marketing purposes. The MFA welcomes membership from all companies that have an interest in private wireless networks. To join the MFA and for more details on membership levels, visit www.multefire.org/join.
For more information on the MFA Certification Program, visit www.multefire.org/certification-program/.
Resources:
- ABI Research White Paper: The Importance of Spectrum Liberalization for Private 5G Networks
- Blog: MulteFire 1.0 Regulatory Analysis White Paper Now Available to MFA Members
- Webpage: Certification FAQ
About the MFA
The MFA is an international association dedicated to building a global ecosystem in support of the common interests of members, developers and users in the application of Long Term Evolution (LTE) and next-generation mobile cellular technology, such as 5G New Radio, in configurations that use unlicensed or shared radio spectrum. For more information about MulteFire technology, its benefits, or how to become a member of the MFA, visit www.MulteFire.org.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201119005382/en/
Contact information
MulteFire Alliance
Lori Mesecke, +1-503-459-9150
press@multefire.org
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
European Commission Approves DAYBU ® (trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European Union24.8.2026 10:01:00 EEST | Press release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the European Commission (EC) has granted marketing authorization for DAYBU (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older, making it the first and only treatment approved for Rett syndrome in the European Union (EU). “The approval of DAYBU marks a significant milestone for the Rett syndrome community in the EU and advances our mission to bring this innovative treatment to patients and families who have long faced a profound unmet medical need,” said Catherine Owen Adams, Acadia’s Chief Executive Officer. “For people living with Rett syndrome, a devastating rare neurodevelopmental disorder, there have been no approved treatment options in the EU. We are proud to make DAYBU available and look forward to supporting patients, caregivers, and healthcare providers gain access to treatment." The DAYBU marketing authorization in the EU is prim
ORZEYFUL (oveporexton) Approved in Japan as the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 124.8.2026 09:36:00 EEST | Press release
Takeda (TOKYO:4502/NYSE:TAK) announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) approved the use of ORZEYFUL (oveporexton) for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults. ORZEYFUL is a first-in-class oral orexin receptor 2 (OX2R) agonist and the only medicine indicated in Japan to treat the disease holistically rather than individual symptoms. The discovery of this new class of medicine originated in Takeda's laboratories in Japan. Takeda is proceeding with launch preparations and expects to make ORZEYFUL available as quickly as possible. “Our discovery of the first orexin agonist is a successful representation of Japan-originated science that will directly impact people around the world living with narcolepsy type 1,” said Julie Kim, president and chief executive officer of Takeda. “With the potential to redefine narcolepsy type 1 care, ORZEYFUL is the first validation of our broader orexin strategy, demonstrating how scientifi
Fasset Hits $1B Valuation as SBI Group Leads $68M Series C to Scale AI-Powered Stablecoin Neobanking24.8.2026 09:03:00 EEST | Press release
Fasset, the AI-powered stablecoin neobanking platform, today announced it has raised $68 million in Series C funding at a $1 billion valuation. The financing was led by SBI Group and follows Fasset’s $51 million Series B earlier this year, which brought Speedinvest onto the cap table alongside a group of strategic investors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260823503947/en/ Mohammad Raafi Hossain, Co-Founder and CEO, Fasset The new capital will support the expansion of Own Network, Fasset’s regulated financial network that connects banks, telcos, payment and liquidity providers to enable settlement across international markets. Fasset will also increase investment in agentic AI-enabled systems supporting corridor banking, stablecoin settlement and tokenized asset infrastructure. After raising Series B in May, Fasset has now raised a total of $119 million in 2026. The financing marks Fasset’s entry into the glob
Zanders Expands DACH Region with New Office in Vienna, Austria24.8.2026 08:11:00 EEST | Press release
Zanders, the global treasury, risk, and technology consultancy, today announced a significant expansion of its DACH region with the opening of a new office in Vienna. The move builds on Zanders' continued growth across Germany, Austria, and Switzerland, and marks another step in the firm's strategy of deepening its presence in the markets where client demand for specialized treasury, risk, and corporate finance advisory is growing fastest. DACH has been one of Zanders' priority regions for several years, with the firm steadily expanding its team and client base across Germany and Switzerland. Austria represents a natural next step in that growth: in conversations with clients in the market, Zanders has seen growing interest in treasury transformation and financing support, as companies work through interest rate volatility, refinancing needs, and a broader shift toward more digitized, centralized treasury operations. The new Vienna office allows Zanders to be closer to clients' operati
Novotech Strengthens Presence in Japan with Opening of Tokyo Office24.8.2026 02:01:00 EEST | Press release
Novotech, a leading global biotech CRO and full-service clinical research organization, has strengthened its established presence in Japan with the opening of a new office in Tokyo. The investment builds on Novotech’s existing operations and clinical trial activity in Japan and further enhances its ability to support Japanese biopharma companies as they advance programs regionally and across key international markets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260823592174/en/ Takeshi Mori, Novotech Country Head, Japan The Tokyo office will serve as a strategic hub for Novotech’s growing operations in Japan, providing enhanced local expertise and strengthening collaboration with clients, partners, research institutions, and innovation ecosystems across the region. Novotech is currently supporting ongoing studies in Japan and provides sponsors with integrated support across early-phase clinical development in Australia, F
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom